Meet @Mel_Bertram , the world class leader in
🧩Health Economics
🧩Modelling
🧩Epidemiology
🧩Health Systems Reforms
🌈(all of them including for) #UHC , #NCDs & #Cancer

Very soon at #Data #Analytics #Delivery4Impact #DDI @WHO
👉who.int/data/ddi

https://twitter.com/decide_health/status/1337031918819405826

Dr Bertram is a well-recognized advocate and technical expert for the #cancer community, for the brilliant work to support efficient & effective global 🌐 cancer control planning!

Find more at: 👇👇👇

A new perspective on drug repurposing, clinical trials and regulatory solutions to boost research for #COVID19 just out on @OncologyAdvance @EORTC #EuropeanJournalofCancer

What #cancer medicines repurposing for COVID19?
sciencedirect.com/science/articl… The high-throughput screening of approved molecules capable to dock to the key protein domains of SARS-CoV-2 pathogenesis or related to the immune-dysregulation has the potential to identify thousands of possible compounds, from in silico models..

While I can feel some discomfort in reviewing reviewers' comments, and I would get upset as a reviewer - feeling a threat to the independency of judgement..

The scientific peer- reviewing process is not a childish joke, to vomit the revenge sedimented there from years.

1/n My take from an interesting dialogue with a high-level editorial board this afternoon can be summarised as:

@ScienceMagazine
sciencemag.org/news/2020/10/d…